XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2

Segment Reporting (Tables)

6 Months Ended

May 31, 2020

Segment Reporting [Abstract]

Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment

The following table shows, by segment: net revenue, cost of sales, depreciation and amortization, operating profit, interest expense, and income tax (expense) benefit for the three and six months ended May 31, 2020 and May 31, 2019:

		For the three months ended May 31, 2020				For the three months ended May 31, 2019
Net revenue
Umbilical cord blood and cord tissue stem cell service		$	7,600,902			$	7,881,697
PrepaCyte®-CB			57,300				12,040
Public cord blood banking			213,642				234,115
Total net revenue		$	7,871,844			$	8,127,852
Cost of sales
Umbilical cord blood and cord tissue stem cell service		$	1,966,441			$	2,218,926
PrepaCyte®-CB			32,014				4,621
Public cord blood banking			482,088				404,744
Total cost of sales		$	2,480,543			$	2,628,291
Depreciation and amortization
Umbilical cord blood and cord tissue stem cell service		$	36,408			$	46,269
PrepaCyte®-CB			6,895				9,065
Public cord blood banking			—				—
Total depreciation and amortization		$	43,303			$	55,334
Operating income
Umbilical cord blood and cord tissue stem cell service		$	2,002,877			$	3,001,600
PrepaCyte®-CB			17,984				(1,644	)
Public cord blood banking			(268,675	)			(2,503,392	)
Total operating income		$	1,752,186			$	496,564
Interest expense
Umbilical cord blood and cord tissue stem cell service		$	365,371			$	424,287
PrepaCyte®-CB			—				—
Public cord blood banking			—				—
Total interest expense		$	365,371			$	424,287
Income tax expense
Umbilical cord blood and cord tissue stem cell service		$	380,010			$	50,943
PrepacCte®-CB			—				—
Public cord blood banking			—				—
Total income tax expense		$	380,010			$	50,943

		For the six months ended May 31, 2020				For the six months ended May 31, 2019
Net revenue
Umbilical cord blood and cord tissue stem cell service		$	15,007,190			$	15,216,724
PrepaCyte ®-CB			117,707				37,760
Public cord blood banking			367,721				368,480
Total net revenue		$	15,492,618			$	15,622,964
Cost of sales
Umbilical cord blood and cord tissue stem cell service		$	4,021,515			$	4,257,530
PrepaCyte ®-CB			73,131				164,627
Public cord blood banking			889,041				672,361
Total cost of sales		$	4,983,687				5,094,518
Depreciation and amortization
Umbilical cord blood and cord tissue stem cell service		$	73,735			$	94,186
PrepaCyte®-CB			13,789				18,128
Public cord blood banking			—				—
Total depreciation and amortization		$	87,524			$	112,314
Operating income
Umbilical cord blood and cord tissue stem cell service		$	3,492,424			$	4,131,863
PrepaCyte®-CB			30,379				(144,993	)
Public cord blood banking			(521,547	)			(2,636,644	)
Operating income		$	3,001,256			$	1,350,226
Interest expense
Umbilical cord blood and cord tissue stem cell service		$	730,670			$	831,212
PrepaCyte®-CB			—				—
Public cord blood banking			—				—
Total interest expense		$	730,670			$	831,212
Income tax expenses
Umbilical cord blood and cord tissue stem cell service		$	632,390			$	155,610
PrepaCyte®-CB			—				—
Public cord blood banking			—				—
Total income taxes		$	632,390			$	155,610

The following table shows the assets by segment as of May 31, 2020 and November 30, 2019:

		As of May 31, 2020				As of November 30, 2019
Assets
Umbilical cord blood and cord tissue stem cell service		$	31,238,744			$	28,975,002
PrepaCyte®-CB			287,448				289,804
Public cord blood banking			13,314,420				13,621,354
Total assets		$	44,840,612			$	42,886,160

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration